Literature DB >> 31831634

Impact of TCR Diversity on the Development of Transplanted or Chemically Induced Tumors.

Hans Schreiber1, Matthias Leisegang2, Karin Schreiber3, Theodore G Karrison4, Steven P Wolf3,2, Kazuma Kiyotani5, Madeline Steiner3, Eric R Littmann6, Eric G Pamer6, Thomas Kammertoens2.   

Abstract

Burnet postulated that the diversity of T-cell receptors (TCR) allows T cells to protect against the development of cancers that display antigens with a similar, seemingly endless diversity. To test this hypothesis, we developed a strategy in which a single breeding pair of mice gives rise to four groups of sibling mice. Three of the four groups had a similar number of CD8+ T cells, but TCR diversity was either broad, significantly reduced, or absent when expressing only one type of TCR. The fourth group had no T cells. All mice shared the same housing, and, therefore, their microbial environment was similar. Only slight differences in the intestinal flora were observed under these conditions. An undisturbed broad TCR repertoire was required for the rejection of inoculated cancers displaying the natural antigenic heterogeneity of primary tumors, whereas even one type of TCR was sufficient to protect against artificial cancers stably expressing cognate antigens. The three groups of mice with limited or no TCR repertoire showed an increased risk of developing primary tumors after chemical induction. However, the risk of early death or morbidity in these cohorts of mice was significantly higher than in mice with a diverse TCR repertoire, and it remains unknown whether mice with reduced TCR diversity, who died early without cancer, would have developed tumors with higher, lower, or equal probability after induction. Together, TCR diversity seems crucial to overcome the natural genetic instability of cancers and their antigenic heterogeneity, which impacts the design of cellular therapies. ©2019 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31831634      PMCID: PMC7007920          DOI: 10.1158/2326-6066.CIR-19-0567

Source DB:  PubMed          Journal:  Cancer Immunol Res        ISSN: 2326-6066            Impact factor:   11.151


  77 in total

1.  The need for littermate controls.

Authors:  Rikard Holmdahl; Bernard Malissen
Journal:  Eur J Immunol       Date:  2012-01       Impact factor: 5.532

2.  Design of 16S rRNA gene primers for 454 pyrosequencing of the human foregut microbiome.

Authors:  Carlos W Nossa; William E Oberdorf; Liying Yang; Jørn A Aas; Bruce J Paster; Todd Z Desantis; Eoin L Brodie; Daniel Malamud; Michael A Poles; Zhiheng Pei
Journal:  World J Gastroenterol       Date:  2010-09-07       Impact factor: 5.742

Review 3.  'Final common pathway' of human cancer immunotherapy: targeting random somatic mutations.

Authors:  Eric Tran; Paul F Robbins; Steven A Rosenberg
Journal:  Nat Immunol       Date:  2017-02-15       Impact factor: 25.606

4.  Chemically induced sarcomas from nude mice are more immunogenic than similar sarcomas from congenic normal mice.

Authors:  I M Svane; A M Engel; M B Nielsen; H G Ljunggren; J Rygaard; O Werdelin
Journal:  Eur J Immunol       Date:  1996-08       Impact factor: 5.532

5.  Perforin and interferon-gamma activities independently control tumor initiation, growth, and metastasis.

Authors:  S E Street; E Cretney; M J Smyth
Journal:  Blood       Date:  2001-01-01       Impact factor: 22.113

6.  Immune surveillance against a solid tumor fails because of immunological ignorance.

Authors:  A F Ochsenbein; P Klenerman; U Karrer; B Ludewig; M Pericin; H Hengartner; R M Zinkernagel
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-02       Impact factor: 11.205

7.  Adaptive immunity maintains occult cancer in an equilibrium state.

Authors:  Catherine M Koebel; William Vermi; Jeremy B Swann; Nadeen Zerafa; Scott J Rodig; Lloyd J Old; Mark J Smyth; Robert D Schreiber
Journal:  Nature       Date:  2007-11-18       Impact factor: 49.962

Review 8.  Histologic Lesions Induced by Murine Norovirus Infection in Laboratory Mice.

Authors:  C C Hsu; S L Piotrowski; S M Meeker; K D Smith; L Maggio-Price; P M Treuting
Journal:  Vet Pathol       Date:  2016-01-20       Impact factor: 2.221

9.  Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice.

Authors:  D H Kaplan; V Shankaran; A S Dighe; E Stockert; M Aguet; L J Old; R D Schreiber
Journal:  Proc Natl Acad Sci U S A       Date:  1998-06-23       Impact factor: 11.205

10.  SILVA: a comprehensive online resource for quality checked and aligned ribosomal RNA sequence data compatible with ARB.

Authors:  Elmar Pruesse; Christian Quast; Katrin Knittel; Bernhard M Fuchs; Wolfgang Ludwig; Jörg Peplies; Frank Oliver Glöckner
Journal:  Nucleic Acids Res       Date:  2007-10-18       Impact factor: 16.971

View more
  6 in total

Review 1.  A Darwinian perspective on tumor immune evasion.

Authors:  Julieann Puleo; Kornelia Polyak
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2021-12-18       Impact factor: 10.680

Review 2.  Criteria to make animal studies more relevant to treating human cancer.

Authors:  Steven P Wolf; Frank T Wen; Hans Schreiber
Journal:  Curr Opin Immunol       Date:  2021-10-04       Impact factor: 7.486

Review 3.  Thymic Function Associated With Cancer Development, Relapse, and Antitumor Immunity - A Mini-Review.

Authors:  Weikan Wang; Rachel Thomas; Olga Sizova; Dong-Ming Su
Journal:  Front Immunol       Date:  2020-04-30       Impact factor: 7.561

Review 4.  Contribution of Macrophages and T Cells in Skeletal Metastasis.

Authors:  Veronica Mendoza-Reinoso; Laurie K McCauley; Pierrick G J Fournier
Journal:  Cancers (Basel)       Date:  2020-04-20       Impact factor: 6.639

5.  Hepatocellular carcinoma-infiltrating γδ T cells are functionally defected and allogenic Vδ2+ γδ T cell can be a promising complement.

Authors:  Wenjing He; Yi Hu; Dan Chen; Yijia Li; Dongmei Ye; Qiang Zhao; Li Lin; Xiaomin Shi; Ligong Lu; Zhinan Yin; Xiaoshun He; Yifang Gao; Yangzhe Wu
Journal:  Clin Transl Med       Date:  2022-04

6.  Revisit the signatures of γδ T cells in hepatocellular carcinoma.

Authors:  Yanan Gao; Maojun You; Pengyuan Yang
Journal:  Clin Transl Med       Date:  2022-05
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.